An S&P 500 Global Biopharmaceutical

An S&P 500 Global Biopharmaceutical

An S&P 500 global biopharmaceutical lacked the reliable data needed for efficient, agile new drug launches. They had unique data management challenges due to extreme growth with several new drugs pending approval, while also facing the risk of violating various spend compliance reporting requirements. They needed a modern approach to data management to manage customer information as well as meet regulatory requirements.

11-v2.png

Reltio Cloud helped them consolidate health care provider (HCP) and health care organization (HCO) data from all sources to support compliance with the Physician Payments Sunshine Act & other reporting requirements including 3rd-party data change request and verification process.

Reltio Cloud with a graph-based backend gave us agility and speed to build our master data needs for several business areas.
— VP R&D IT